Tags

Type your tag names separated by a space and hit enter

Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients.
Retina. 2013 Jul-Aug; 33(7):1435-40.R

Abstract

PURPOSE

To evaluate the safety and efficacy of Ozurdex (dexamethasone intravitreal implant) 0.7 mg in the treatment of uveitic macular edema in vitrectomized eyes.

METHODS

Data from 13 patients (17 eyes) with persistent uveitic cystoid macular edema and a history of pars plana vitrectomy in the study eyes that were treated with intravitreal injection of 0.7-mg dexamethasone implant were reviewed retrospectively. Main outcome measures were changes in central retinal thickness measured by optical coherence tomography and changes in best-corrected visual acuity.

RESULTS

The median age of patients was 61 years (range, 19-81 years). The median duration of uveitic macular edema was 12 months (range, 2-72 months). The mean baseline central retinal thickness (95% confidence interval) was 461.6 μm (403.8-519.4), decreased to 277.2 μm (244.6-309.8) at 4 weeks (P < 0.01), remained low at 349.9 μm (281.8-418.0) at 3 months (P = 0.01), and then reached 394.1 μm (328.3-459.8) at 6 months (P = 0.14). After 3 months, there was a median improvement of 2 lines of best-corrected visual acuity, with 52.9% of eyes gaining 2 lines or more (P < 0.01). At 6 months, there were 5 eyes that maintained the 2 lines gain and none had lost >1 line from baseline (P = 0.03). In 8 eyes (47.1%), reinjection of the implant was performed at a mean of 6.5 months. Ocular hypertension (47.1%), hypotony (11.8%), anterior chamber displacement of the implant (5.9%), and glaucoma, which required filtration surgery (5.9%), were the most common adverse events. Mean follow-up was 9.6 months (range, 6-17 months).

CONCLUSION

In this small case series of eyes with limited follow-up, treatment with dexamethasone intravitreal implant injection for uveitic macular edema in vitrectomized eyes was associated with favorable visual outcomes and had an acceptable safety profile.

Authors+Show Affiliations

Ophthalmology Institute, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain. amadan@clinic.ub.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23514796

Citation

Adán, Alfredo, et al. "Dexamethasone Intravitreal Implant for Treatment of Uveitic Persistent Cystoid Macular Edema in Vitrectomized Patients." Retina (Philadelphia, Pa.), vol. 33, no. 7, 2013, pp. 1435-40.
Adán A, Pelegrín L, Rey A, et al. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina. 2013;33(7):1435-40.
Adán, A., Pelegrín, L., Rey, A., Llorenç, V., Mesquida, M., Molins, B., Ríos, J., & Keller, J. (2013). Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina (Philadelphia, Pa.), 33(7), 1435-40. https://doi.org/10.1097/IAE.0b013e31827e247b
Adán A, et al. Dexamethasone Intravitreal Implant for Treatment of Uveitic Persistent Cystoid Macular Edema in Vitrectomized Patients. Retina. 2013 Jul-Aug;33(7):1435-40. PubMed PMID: 23514796.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. AU - Adán,Alfredo, AU - Pelegrín,Laura, AU - Rey,Amanda, AU - Llorenç,Victor, AU - Mesquida,Marina, AU - Molins,Blanca, AU - Ríos,José, AU - Keller,Johannes, PY - 2013/3/22/entrez PY - 2013/3/22/pubmed PY - 2014/1/30/medline SP - 1435 EP - 40 JF - Retina (Philadelphia, Pa.) JO - Retina VL - 33 IS - 7 N2 - PURPOSE: To evaluate the safety and efficacy of Ozurdex (dexamethasone intravitreal implant) 0.7 mg in the treatment of uveitic macular edema in vitrectomized eyes. METHODS: Data from 13 patients (17 eyes) with persistent uveitic cystoid macular edema and a history of pars plana vitrectomy in the study eyes that were treated with intravitreal injection of 0.7-mg dexamethasone implant were reviewed retrospectively. Main outcome measures were changes in central retinal thickness measured by optical coherence tomography and changes in best-corrected visual acuity. RESULTS: The median age of patients was 61 years (range, 19-81 years). The median duration of uveitic macular edema was 12 months (range, 2-72 months). The mean baseline central retinal thickness (95% confidence interval) was 461.6 μm (403.8-519.4), decreased to 277.2 μm (244.6-309.8) at 4 weeks (P < 0.01), remained low at 349.9 μm (281.8-418.0) at 3 months (P = 0.01), and then reached 394.1 μm (328.3-459.8) at 6 months (P = 0.14). After 3 months, there was a median improvement of 2 lines of best-corrected visual acuity, with 52.9% of eyes gaining 2 lines or more (P < 0.01). At 6 months, there were 5 eyes that maintained the 2 lines gain and none had lost >1 line from baseline (P = 0.03). In 8 eyes (47.1%), reinjection of the implant was performed at a mean of 6.5 months. Ocular hypertension (47.1%), hypotony (11.8%), anterior chamber displacement of the implant (5.9%), and glaucoma, which required filtration surgery (5.9%), were the most common adverse events. Mean follow-up was 9.6 months (range, 6-17 months). CONCLUSION: In this small case series of eyes with limited follow-up, treatment with dexamethasone intravitreal implant injection for uveitic macular edema in vitrectomized eyes was associated with favorable visual outcomes and had an acceptable safety profile. SN - 1539-2864 UR - https://www.unboundmedicine.com/medline/citation/23514796/Dexamethasone_intravitreal_implant_for_treatment_of_uveitic_persistent_cystoid_macular_edema_in_vitrectomized_patients_ L2 - https://doi.org/10.1097/IAE.0b013e31827e247b DB - PRIME DP - Unbound Medicine ER -